 |
|
Incomplete Financial Disclosure in a Study of Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: We would like to report an incomplete financial disclosure in our study of escitalopram and problem-solving therapy for prevention of poststroke depression,1 resulting from erroneous recollection of the appropriate dates for speaking presentations sponsored by pharmaceutical companies and ownership of pharmaceutical stock.
In September 2003, Dr Robinson received financial support for expenses from Lubeck to present his research data at a meeting of the Consultation Psychiatrists of the European Union in Spain; no honorarium was paid. In October 2004, he received honoraria and expenses for 2 presentations in Tucson, Arizona, which were sponsored by Forest Laboratories and paid through the intermediary, Sudler and Hennessey, New York, New York. He was a member of the speakers' bureau for Forest Laboratories in 2004 and perhaps 2005, but this was the only presentation during the 5-year reporting window from 2003 to 2008. In November 2004, he was paid an honorarium . . . [Full Text of this Article]
Robert G. Robinson, MD
robert-robinson@uiowa.edu
Stephan Arndt, PhD
Department of Psychiatry
University of Iowa
Iowa City
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Escitalopram and Problem-Solving Therapy for Prevention of Poststroke Depression: A Randomized Controlled Trial
Robert G. Robinson, Ricardo E. Jorge, David J. Moser, Laura Acion, Ana Solodkin, Steven L. Small, Pasquale Fonzetti, Mark Hegel, and Stephan Arndt
JAMA. 2008;299(20):2391-2400.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Resolving Unreported Conflicts of Interest
DeAngelis and Fontanarosa
JAMA 2009;302:198-199.
FULL TEXT
|
